Business
Century Therapeutics Announces New Beta Islet Program for Type 1 Diabetes
Allo-Evasion™ 5.0-engineered iPSC beta islets are designed to overcome immune rejection and provide durable glucose control without chronic immunosuppressionCompelling preclinical data demonstrate rapid reversal of diabetes and sustained normoglycemia, human C‑peptide production and mature GSIS, supported by scalable bioreactor-based manufacturingInvestigational New Drug (IND)-enabling studies on track to initiate by year-end 2025; IND submission planned as early as 2026 PHILADELPHIA, Nov. 13, 2
About this update from Century Therapeutics, Inc.
[{"type":"image","alt":"Century Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Century Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":89,"url":"https://media.zenfs.com/en/globenewswire.com/1dafc8564c4cf69fd2fbdeedd53053be"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/1qMMhZqDcCAAdTlry0aLDQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/1dafc8564c4cf69fd2fbdeedd53053be","width":300,"height":89}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Allo-Evasion™ 5.0-engineered iPSC beta islets are designed to overcome immune rejection and provide durable glucose control without chronic immunosuppression","length":157,"tagName":"p"}]},{"val":[{"type":"text","content":"Compelling preclinical data demonstrate rapid reversal of diabetes and sustained normoglycemia, human C‑peptide production and mature GSIS, supported by scalable bioreactor-based manufacturing","length":192,"tagName":"p"}]},{"val":[{"type":"text","content":"Investigational New Drug (IND)-enabling studies on track to initiate by year-end 2025; IND submission planned as early as 2026","length":126,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":475,"olType":false},{"type":"text","content":"PHILADELPHIA, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases and cancer, today announced its first program for Type 1 diabetes (T1D), CNTY-813. The program comprises iPSC-derived beta islets engineered with the company’s proprietary Allo-Evasion™ 5.0 technology, designed to protect from T cell, NK cell and humoral immune rejection, with the goal of durable glycemic control without the need for systemic immunosuppression.","length":584,"tagName":"p"},{"type":"text","content":"“With our cell foundry and Allo-Evasion™ 5.0 technology, we have engineered iPSC derived beta islets that we believe can deliver durable glycemic control without chronic immunosuppression,” said Chad Cowan, Ph.D., Chief Scientific Officer of Century Therapeutics. “After initiating discovery activities earlier this year, we have now generated compelling preclinical data that underscores the deep potential of this program, i...